{
    "clinical_study": {
        "@rank": "144760", 
        "arm_group": {
            "arm_group_label": "Observational group", 
            "description": "Subjects in the period less than 48 weeks after the final administration of GX-188E"
        }, 
        "biospec_descr": {
            "textblock": "plasma and PBMC (peripheral blood mononeuclear cells)"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This study is to follow up on the change of immune response by measuring HPV type 16/18 E6\n      and E7 specific T cell response and lesion condition in subjects who have administered in\n      DNA-based therapeutic vaccine."
        }, 
        "brief_title": "Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Intraepithelial Neoplasia 3", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Cervical Intraepithelial Neoplasia", 
                "Carcinoma in Situ"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a follow-up study to investigate the change of immunogenicity and lesion condition\n      in subjects with cervical intraepithelial neoplasia (CIN) 3 who have enrolled and completed\n      GX-188E phase I study.\n\n      Subjects will make visits at week 48 (V1) and week 72 (V2) after the final administration of\n      GX-188E.\n\n      The endpoints are to evaluate the change of immune response, involved lesion and infection\n      status compared to that of the final visit in phase I study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female aged between 20 and 50 (inclusive)\n\n          -  The subjects who have visited within 48 weeks after final injection of GX-188E\n\n          -  Those who voluntarily signed informed consent form\n\n        Exclusion Criteria:\n\n          -  Prior participation in any clinical trial within 30 days prior to the visit 1\n\n          -  Any other ineligible condition at the discretion of the investigator that would be\n             ineligible to participate the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The subjects who have completed the DNA vaccine administration of each dosage (1, 2 and 4\n        mg).\n\n        The subjects in the period less than 48 weeks after the final administration of GX-188E"
            }
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100085", 
            "org_study_id": "GX-188E-FU"
        }, 
        "intervention": {
            "arm_group_label": "Observational group", 
            "description": "In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.", 
            "intervention_name": "GX-188E", 
            "intervention_type": "Biological", 
            "other_name": "GX-188E administerd by eletrophoration"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase 1 follow up", 
            "Cervical Intraepithelial Neoplasia", 
            "Adult", 
            "Safety", 
            "Efficacy"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Korea"
                }, 
                "name": "Cheil General Hospital & Women's Healthcare Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Single Center, Phase I Study to Follow-up on the Change of Immunogenicity and Lesion Condition in Subjects Who Have Completed the Phase I GX-188E Trial (Protocol no. GX-188E-SN)", 
        "overall_official": {
            "affiliation": "Cheil General Hospital & Women's Healthcare Center", 
            "last_name": "Tae Jin Kim, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "It would be determined by evaluating HPV type 16/18 E6 and E7 specific T cell response (IFN-\u03b3 ELISPOT assay) using PBMC obtained at week 0 and 24 visit.", 
            "measure": "The change of the immune response compared to that of the final visit in phase I study", 
            "safety_issue": "Yes", 
            "time_frame": "at week 0 and 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100085"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The changes of histological test, cytological test and HPV infection status  would be compared to that of the last visit in phase I study", 
                "measure": "The change of the involved lesion and HPV infection status", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and 24"
            }, 
            {
                "description": "Safety profile would be examined by vital signs, physical examination, clinical laboratory tests etc", 
                "measure": "Safety profile", 
                "safety_issue": "No", 
                "time_frame": "at week 0 and 24"
            }
        ], 
        "source": "Genexine, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genexine, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}